• Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements
• In May, the company received Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial of its lead candidate, REQORSA(R) Immunogene Therapy
• The Phase 1 dose escalation portion of the study showed that REQORSA(R) was generally well tolerated, and there were no dose-limiting toxicities; Genprex also reported encouraging evidence of efficacy in this portion
• In April, Genprex announced that its research collaborators presented in vivo mouse data showing that Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System could be successfully used to deliver a second tumor suppressor gene with strong pre-clinical evidence of efficacy
• Based on these findings, Dr. Berger states that the ONCOPREX Nanoparticle Delivery System has been validated as a platform for reexpressing tumor suppressor gene proteins in cancer cells

Mark Berger, M.D., Chief Medical Officer of Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing gene therapies for patients with cancer and diabetes was featured in a recent Bell2Bell Podcast episode (https://ibn.fm/ZnVPJ).

Dr. Berger talked about the Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of Genprex’s Acclaim-1 clinical trial of REQORSA(R) , Genprex’s lead drug candidate, in combination with AstraZeneca’s Tagrisso (osimertinib) to treat late-stage non-small cell lung cancer (“NSCLC”)  He also spoke about  the news that the company’s non-viral ONCOPREX(R) Nanoparticle Delivery System has shown preclinical evidence of successusing a second tumor suppressor gene.

“We’re very excited about both of these events. I think it portends a great deal of other progress through the course of this year, and that’s what we hope to be able to bring to you and talk to you about at other times during the year,” said Dr. Berger.

Announced May 30, the SRC approval was based on preliminary safety data from the Phase 1 dose escalation portion of its Acclaim-1 clinical trial that showed that REQORSA was generally well tolerated and that there were no dose-limiting toxicities (https://ibn.fm/OmHND). As a result, the committee determined that the recommended Phase 2 dose of REQORSA will be 0.12 mg/kg, the highest dose level delivered in the Phase 1 portion. And as Dr. Berger further explained during the conversation, “The number won’t mean much, but it is twice the dose used previously in our prior studies and was found to be safe during these evaluations.”

The company announced the positive preliminary clinical data from the Phase 1 portion in an abstract published at the 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting, from where Dr. Berger was speaking to Bell2Bell Podcast listeners. ASCO, Dr. Berger conveyed, is the largest clinical oncology meeting of the year. Last year, it brought together 42,000 clinical oncologists, 30,000 of whom attended physically, with the rest listening virtually. “We expect the same number today. So, this is a huge meeting with lots of information and new data,” Dr. Berger said.

In addition to announcing the safety and tolerability profile of REQORSA, Genprex also reported encouraging evidence of efficacy in the Phase 1 portion of the Acclaim-1 study. With the SRC approval granted, Genprex expects to begin the Phase 2 expansion portion of the study in Q3 of 2023. This portion is expected to enroll about 66 patients, divided into two cohorts. The first cohort, comprising half the enrolled number, will include patients who received only prior Tagrisso treatment. The other cohort will be made up of patients who received Tagrisso treatment and chemotherapy. This enrollment format is intended to help the company determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints. Genprex will also conduct an interim analysis for each cohort following the treatment of 19 patients in that cohort.

Meanwhile, Genprex announced in April that its research collaborators presented positive preclinical data for the  reexpression of the NPRL2 gene. The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (“AACR”) annual meeting, held in April.

According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver the NPRL2 tumor suppressor gene “positions Genprex to expand our clinical pipeline with a new drug candidate” and gives the company “further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”

“The preclinical data also provide further evidence that the ONCOPREX(R) Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA(R),” Varner continued in the company’s April 19 news release (https://ibn.fm/jusfJ).

So far, and through testing involving TUSC2 and NPRL2, the company has shown major detrimental preclinical effects on the growth and survival of cancer cells. Thus, the ONCOPREX(R) Nanoparticle Delivery System has emerged as “really a platform for delivering tumor suppressor gene expression into cancer cells,” according to Dr. Berger.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Cepton integrated Vista-X120 Plus lidar into NVIDIA Omniverse platform to enable real-time simulation and 3D visualization to streamline lidar deployment processes and reduce cost for automakers
• Vista-X120 Plus features a software-definable ROI, allows users to dynamically adjust and optimize lidar performance and power consumption based on specific scenarios or areas that require additional attention
• Cepton released a financial update revealing it was on track to receive final production validation for salable vehicles and continue shipment of pre-production lidar units for multiple vehicle models
• Additional update highlights included completed implementation of embedded lidar software, and execution of RFQ and RFI responses for top OEMs in the consumer vehicles and trucking spaces

The NVIDIA Omniverse platform enables real-time simulation and 3D visualization for metaverse applications by providing a shared virtual environment where users can collaborate to engineer real-world scenarios. Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, recently gave the Omniverse an upgrade by integrating its Vista-X120 Plus lidar into DRIVE Sim, an end-to-end simulation application built on the platform (https://ibn.fm/AXC4l).

Cepton was one of the first companies to demonstrate a 360°-coverage, dual-range lidar simulation that detected long-range obstacles and eliminated near-range blind spots. The addition of the Vista-X120 Plus into the Omniverse builds upon previous integrations to give AV developers access to simulated sensor data for use in developing and testing autonomous driving algorithms, sensors, and software.

“The addition of the Cepton Vista-X120 Plus lidar model to NVIDIA Omniverse provides greater flexibility to AV developers, accelerating technology development and reducing cost.” said Zvi Greenstein, General Manager at NVIDIA.

The Vista-X120 Plus features a software-definable region of interest (“ROI”) that allows users to dynamically adjust and optimize lidar performance and power consumption based on specific scenarios or areas that require additional attention. The model additionally offers specific visualizations based on placement, as was shown in a video demonstrating simulated point clouds generated from a sensor integrated into the vehicle’s roof (https://ibn.fm/Bdxwg).

“As the video demonstrates, our Vista-X120 Plus enables adaptive 3D perception capabilities that can truly help vehicles focus on what matters on the road,” said Dr. Dongyi Liao, Chief Technology Officer at Cepton. “Requirements on a lidar’s range, resolution and power consumption vary across different use cases, for example, highway cruising and navigating a busy neighborhood. With a software-definable ROI, Vista-X120 Plus provides an extremely flexible and versatile solution for assisted and autonomous driving.”

In collaboration with top automotive OEMs, Cepton actively strives to commercialize lidar for mass production of advanced driver assistance systems (“ADAS”). The company recently released a financial update that revealed it was on track to receive final production validation for salable vehicles and that it was continuing shipment of pre-production lidar units for multiple vehicle models (https://ibn.fm/h4CdT). Other highlights from the release included the completed implementation of embedded lidar software, and the execution of RFQ and RFI responses for top OEMs in the consumer vehicles and trucking spaces.

“We started fiscal year 2023 with strong progress on our commercial activities,” said Jun Pei, Cepton’s Co-Founder and CEO. “We are hyper-focused on recent RFQ activity with two top global OEMs. Cepton’s recently announced expanded ASIC chipset will further separate us from our peers and drive lidar adoption in consumer vehicles for automotive series production.”

Cepton additionally advances lidar-based solutions for smart cities, smart spaces, and smart industrial applications. The company aims to leverage its patented technology to take lidar mainstream through a balanced approach to performance, cost, and reliability that enables scalable and intelligent 3D perception solutions across numerous industries.

For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD
• Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study
• Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) and epilepsy (EPIL-A21-1).

In March, Lexaria announced that it had completed initial testing using DehydraTECH-CBD in its diabetes animal model study. It initially produced three positive outcomes, including weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. After the initial testing, Lexaria undertook an additional round of analysis to explore other study outcomes, including using an additional blood glucose assay detection system with higher detection sensitivity than was used in the first round of testing.

Using the Antech hexokinase blood chemistry test panel methodology, the company discovered that blood glucose levels were statistically significantly lowered by 19.9 ± 7% in the obese diabetic-conditioned animals treated with the DehydraTECH-CBD 30 mg/Kg dose. This finding appears to be a discovery of a property not generally known to be associated with generic CBD treatment. The findings in DIAB-A22-1 and DehydraTECH-CBD’s ability to reduce animal blood sugar levels are extremely encouraging for Lexaria and warrant additional research.

Lexaria announced dementia study DEM-A22-1 in November 2022 to investigate whether DehydraTECH-CBD enables pro-cognitive performance enhancements in its model, potentially for use in dementia treatment. Although findings were generally unremarkable and several unexpected study complications may have muted efficacy distinction ability, the company recognizes that previous research by other investigators using CBD in this animal model has required dosing over a longer duration. Lexaria will consider this if further testing is considered in the future – including with DehydraTECH-processed nicotine as another agent known to enhance cognitive performance when delivered effectively.

Also announced in November 2022, Lexaria completed two parts of its EPIL-A21-1 study designed to evaluate the effectiveness of DehydraTECH-CBD in comparison to one of the world’s leading anti-seizure medications, Epidiolex(R), in reducing seizure activity using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation. Findings of the initial study appear to demonstrate that DehydraTECH-CBD had effectiveness at lower dosages and faster than Epidiolex(R).

Since the initial announcement, Lexaria has completed the final electrical stimulation study under EPIL-A21-1, which was designed to establish an ED50 (the dose required to achieve seizure inhibition in 50% of the animals tested) for DehydraTECH-CBD in this animal model. This ED50 study was designed to corroborate prior findings.

Lexaria was able to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model, which compared favorably to Epidiolex(R), which generally requires a higher dose of 100 mg/Kg to achieve the same results.

Since the development of DehydraTECH in 2014, Lexaria has yielded 34 granted patents, with many more pending patents in countries worldwide. The benefits of using this patented technology include the delivery of bioactive substances via oral ingestion without the need for unhealthy practices of inhalational dosing and without the need for co-administration with unhealthy sugars or sweeteners commonly used to mask bitter tastes. Lexaria is testing its technology for various indications and needs currently unmet by available medical treatments.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis
• Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration
• Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, just announced that it has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). The license agreement is part of a broad-based collaboration with the Max Planck Society and the University of Medical Center Göttingen (“UMG”). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis (https://ibn.fm/zifs4).

BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany, is producing a pipeline of innovative therapies addressing diseases underserved by current treatments, yet with large and growing markets. Previous development efforts have addressed diseases such as Covid-19, and BiondVax’s current venture with these two institutions is geared towards creating NanoAbs that target the large, underserved market of psoriasis, a chronic autoimmune disease that causes inflammation and scaling of the skin.

The condition affects over 7.5 million adults in the U.S. and an estimated 125 million people worldwide, yet currently available monoclonal antibodies (“mAbs”) therapies for the condition require an inconvenient systemic injection every four to eight weeks and come with adverse side effects, including exacerbation of Inflammatory Bowel Disease (“IBD”) (https://ibn.fm/rwg69). With BiondVax’s NanoAbs, it is possible to target not only IL-17A but also IL-17F and IL-17A/F complex, potentially generating superior efficacy in treating the condition.

Mr. Amir Reichman, BiondVax’s CEO, has lauded this exclusive license agreement, expressing his optimism that the company’s NanoAbs have the potential to provide a much-needed and vastly improved treatment option. He also termed it as a validation of the productivity of the collaboration among the three parties.

“The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases but another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” he noted.

According to Dr. Dieter Link, patent and licensing manager at Max Planck Innovation, this milestone marks a significant step toward the clinical application of the next VHH antibody candidates out of the larger group of NanoAbs contemplated by the collaborators.

“We are very pleased that the next antibody candidates out of a larger group pursued by the collaborators have successfully been generated, discovered, and characterized by the Max Planck Institute of Multidisciplinary Sciences,” he noted.

“BiondVax is well positioned to move this closer to and into clinical application,” he added.

BiondVax’s NanoAb platform has proven to have the potential to address a growing range of unmet medical needs. The company remains committed to developing innovative therapies that improve patients’ lives, with the recent exclusive Max Planck license key evidence of the potential for success in achieving BiondVax’s important goals.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Electronic Servitor Publication Network recently signed a client agreement with Investor Brand Network (“IBN”), providing access to its managed digital engagement and activation services
• The agreement seeks to enhance IBN’s growth by helping the company reach new target markets to promote its brands and content distribution network
• XESP provides digital engagement and activation solutions that use sophisticated data analysis and smart technology, providing client companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers
• The company helps clients drive growth

Electronic Servitor Publication Network (OTCQB: XESP), a growth-focused digital activation and engagement solutions innovator and provider targeting B2B companies, recently announced the signing of a client agreement with Investor Brand Network (“IBN”), a multifaceted financial news and publishing company consisting of more than 60 trusted investor-facing brands (https://ibn.fm/a0nBS).

The agreement seeks to enhance IBN’s growth by enabling the company to reach deeper into their current target markets and to access new markets. IBN gains full access to XESP’s managed digital engagement and activation services, including the proprietary Digital Engagement Engine(TM), to promote its brands and content distribution network of more than 5,000 key syndication outlets that help generate greater awareness for its clients.

“We are excited about our relationship with IBN, the clear service and thought leader in their field, to help them achieve their growth goals. We also look forward to exploring the synergies and new opportunities that our partnership will undoubtedly provide for XESP,” said Peter Hager, CEO of Electronic Servitor Publication Network.

Founded in October 2021, XESP is at the forefront of the digital transformation that is taking over B2B markets. XESP has positioned itself as the go-to company for clients looking for growth through optimizing their digital contact with target audiences in non-face-to-face situations. The company has developed a sophisticated technology stack that, coupled with its proven processes and workflows, provides real time data to client companies, enabling a dynamic and personalized connection between them and their target audiences.

“And in the end, it’s all about growth,” said Hager in a recent interview with Proactive Investors (https://ibn.fm/7nnFh). This is because XESP drives better interactions, facilitating better results for its clients. It also solves content management and optimization deficiencies in a fast-moving economy and market, thus guaranteeing its relevance. Moreover, XESP helps its customers preserve margins through efficiency.

One of the solutions in this technology stack is the Digital Engagement Engine(TM). The company’s website explains that this technology “utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift for content providers (https://ibn.fm/X7W0c).

The Digital Engagement Engine(TM) uses sophisticated data analysis and smart technology, providing companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers.

As a growth-stage company, Electronic Servitor Publication Network is currently acquiring customers. “And again, we are very focused on who we acquire as much as they should be focused on us,” Hager explained. One of the elements XESP expects in potential customers is their capacity and capability to continue to grow. XESP then probes the circumstances and challenges that may have led to slow growth or plateaued operations. And using this knowledge, its technology stack, and managed service, the company implements strategies that unlock the desired growth. “Our Growth as a Service business model is focused on what is most important for our clients—producing results,” Hager continued.

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Critical elements including graphite have become not only a necessity for economic prosperity but a national security concern for U.S. policymakers
• Graphite is key for the energy transition because of its role in the lithium-ion battery production for EVs, but the U.S. currently has no graphite production capacity
• Reflex Advanced Materials aims to build domestic production and purification of graphite seeking to sell this critical element at a very high price in a very purified form

Critical minerals, such as cobalt, lithium, and nickel, have become more than fundamental building blocks for clean energy technologies and electric vehicle (“EV”) batteries; they have emerged as the linchpin of national security. Domestic battery manufacturing has run into a problem: some raw materials are only found abroad since many of the minerals essential to EV batteries are primarily mined and processed in China or by businesses influenced by China. In a bid to grapple with the U.S. vulnerabilities due to over-reliance on foreign sources, the Biden Administration introduced measures to strengthen domestic critical and rare minerals supply chains, with more than $100 billion invested so far in EV-related manufacturing (https://ibn.fm/OqYoY). Companies like Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2) offer to revive the domestic critical mineral supply chain in a bid to help the nation’s transition to a clean energy future.

A recent White House report revealed the alarming U.S. vulnerabilities stemming from concentrated supply chains of these essential resources. The 2022 U.S. Geological Survey shows that the U.S. relies entirely on imports for twelve critical minerals and more than fifty percent import-dependent on thirty-one additional minerals. China reigns as the largest source of imports for twenty-six of the fifty minerals classified as critical by the U.S. government (https://ibn.fm/i5svH).

Graphite is one such essential resource. As the largest component of the lithium-ion battery, it is essential to energy transition since EV batteries’ anodes are entirely made of this critical mineral. As one of the forms in which carbon is found in nature, it is abundant in the Earth’s crust and, as such, doesn’t appear to be critical. The problem that makes this mineral critical is that the graphite that goes into EV batteries must be processed – and most of these processing facilities are located abroad, mainly in China. For every 10 million EVs manufactured, between 500,000 and one million tons of graphite are needed – an amount that dwarfs the current total global production of graphite of one million tons. Scaling up production is difficult, as is the effort to replace graphite (https://ibn.fm/XUh42).

As a strategic minerals company committed to locating and developing strategic metals and advanced materials projects, Reflex Advanced Materials aims to improve domestic specialty mineral infrastructure efficiencies to meet the soaring demand from North American manufacturers. This British Columbia-based critical minerals producer seeks to position itself as one of the only North American suppliers of high-purity natural graphite for hi-tech applications after the 60-year-long break in the U.S. domestic graphite production. What Reflex believes that separates the company from its competitors, is that it does not target the graphite mass market but is seeking to sell graphite at a very high price in a very purified form. By partnering with the best-in-class companies, Reflex intends to source world-class battery-grade material from the Ruby Deposit in Montana.

A highly dynamic graphite market is expected in 2023, with forecasts indicating an upward price trajectory as the pace for greener energy sources accelerates and the EV revolution gains momentum (https://ibn.fm/hcPxO). Reflex anticipates to gain a robust competitive advantage as U.S. manufacturers continue to demand American supply in the face of heightened geopolitical tensions and legislative support that aims to incentivize domestic supply chains.

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• Eloro Resources has recently published its ESG program, the next step on its journey toward creating sustainable long-term value for its shareholders
• The policy lays out the company’s objectives within the fields of corporate governance, corporate social responsibility and environmental production
• Eloro Resources has increasingly looked to align its operations with the requirements of its growing stakeholder base
• The company is set to publish its inaugural ESG report in 2023

Mining companies are increasingly seeking to embed sustainability in the way in which they do business as well as across their corporate strategies. Similarly, Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has recently published its ESG program, setting out its commitment towards creating sustainable long-term value for its shareholders by adhering to the best practices in corporate governance (https://ibn.fm/Yw6vw).

A study carried out by consultancy PwC during the Covid-19 pandemic found that mining companies boasting higher ESG ratings outperformed the broader market, delivering 34 percent average total shareholder returns over the preceding three years – ten percentage points higher than the general market index (https://ibn.fm/Olye5). Improved corporate governance, which tends to manifest itself via superior market returns, can also act as a direct corollary towards increased institutional investor interest. Global ESG-linked assets under management are currently on track to grow to $33.8tn by 2026, up from a mere $18.4tn in 2021 – implying that ESG assets are on course to constitute 21.5% of total global AuM within a span of less than 5 years (https://ibn.fm/SN82x).

Eloro Resources has sought to align its strategy with the interests of its stakeholders, recently elaborating on the measures the company is seeking to undertake within the areas of corporate social responsibility, environmental protection, community engagement, health and safety, and corporate governance. In addition to its broader ESG framework, Eloro has established a set of policies with respect to ethical business practices, personal conduct, competition and fair dealings, and disclosure of information that describe its commitment towards promoting effective functioning of personnel and improving corporate performance (https://ibn.fm/9XpI1).

As a result of the above, all directors, officers, and direct and indirect employees are subject to the company’s anti-bribery and anti-corruption policies. In addition, the company has sought to promote an inclusive culture, in the belief that a board and employee base made up of highly qualified individuals from diverse backgrounds may be a means towards enhancing the corporation’s performance by recognizing and utilizing the diverse combination of skills and talents that such a workforce affords.

Whether it relates to the company’s dedication to the local population – 100% of the on-site team is Bolivian; a commitment towards community empowerment – Eloro sponsors regional schools and sports teams in addition to running technology-focused workshops for women; or, taking the necessary measures to ensure its operations are responsive to the environmental needs of nearby communities, Eloro Resources has increasingly sought to translate its ESG-linked ambitions into practice.

Now and as part of the company’s commitment towards the continuous improvement of its governance practices, Eloro has announced that it is planning to complete and publish the corporation’s inaugural ESG report in 2023 – a milestone that follows the publication of the company’s initial mining resource estimate (“MRE”) in the fourth quarter of 2022.

For more information, visit the company’s website at https://elororesources.com/ or view its ESG policies at https://elororesources.com/esg-program.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Ucore Rare Metals Inc. is a critical metals process developer intent on establishing North American-based resources for rare earth element (“REE”) production
• The company has developed its trademarked RapidSX(TM) process for separating REEs from ore deposits, describing it as a faster and more environmentally friendly solution than the industry standard process
• Ucore regards the establishment of a North American-based supply chain for REEs as a critical need to maintain the industry’s independence from China-dominated sourcing and processing
• The U.S. Department of Defense recently awarded Ucore $4 million to demonstrate the capabilities of RapidSX(TM)
• A new NetworkNewsWire (“NNW”) audio broadcast and accompanying editorial outline the efforts of Ucore and a handful of other companies aiming to strengthen North American REE production

More than a decade has passed since the rare earth trades dispute between China, on one side, and several nations including the United States, on the other, erupted over China’s rare earth element (“REE”) export restrictions (https://ibn.fm/0gOCP).

During the interim, the incident has continued to raise alarms as governments and industries search for ways to break China’s iron grip on the global REE supply chain that supplies critical mined resources for modern high-tech devices that range from smartphones and electric vehicle batteries to Abrams tanks and F-35s. An opinion piece published by Fox News in January highlighted the concerns with its headline, “China could shut down our military in a minute if we don’t fix the looming rare earths supply crisis” (https://ibn.fm/gr73H).

China produces 92 percent of the world’s rare earth magnets and performs 85 percent of rare earth processing, as well as 63 percent of rare earth mining (https://ibn.fm/jghLX).

REE processing innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) has been developing technology to disrupt the China-reliant nature of the market, aiming to empower North American industry to extract rare earths from their mined ores using a process superior to the current standard.

An audio broadcast and accompanying editorial recently published by NetworkNewsWire (“NNW”) showcases the efforts of Ucore and a handful of other companies to protect the nations’ access to REEs (https://ibn.fm/GAeEk).

As the editorial notes, Ucore has launched a plant in Canada to demonstrate on a small scale the capabilities of its RapidSX(TM) technology to improve on the standard solvent extraction (“SX”) process for separating REEs from their host ores. And the company is scaling up to commercial production, having acquired a lease for an 80,800 square-foot brownfield facility in Louisiana where it will build its first Strategic Metals Complex (“SMC”) facility for REE separation and oxide production.

The U.S. Department of Defense provided a substantial boost to Ucore’s goals and to the company’s credibility by awarding a $4 million contract to help Ucore demonstrate the effectiveness and America-based capability of its RapidSX(TM) process to the government. Successful completion of the agreement’s requirements could lead to follow-on award opportunities for Ucore to continue its work.

“The full-scale production plant is scheduled to initially process 2,000 tonnes of total rare earth oxides by the end of 2024, increasing to 5,000 tonnes in 2026,” the editorial states (https://ibn.fm/VhoeW). “Management believes that the cost of the company’s facilities will be supported by local and state government incentives as well as prepurchase (off-take) agreements from major manufacturers currently under development. All of this aligns with the final primary purpose of the $4 million DoD contract.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Cepton recently revealed that its lidar technology has been deployed to bolster traffic infrastructure in Texas and Utah
• The announcement marks a continued trend, which has seen Cepton’s lidar solutions increasingly used to facilitate traffic management and smart city infrastructure – most recently announcing their multi-million contract with a leading U.S. tolling system operator
• With the company seeing growing business opportunities, as well as being fully committed to executing its flagship lidar series production program by a Top 3 automotive OEM, Cepton has looked to take the next step in its journey with the addition of Luis Gonçalves to its Detroit team
• Gonçalves will join as Director of Customer Programs and will be charged with helping Cepton bolster production volumes whilst simultaneously seeking to exploit new commercial opportunities

Lidar has firmly established its position within in-car technology, but in the city of Arlington, Texas, the technology solution may be on its way towards becoming part of the critical infrastructure on street level. Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer of high-performance MMT(TM) lidar solutions, recently revealed that its lidar technology had been used in a series of groundbreaking studies in Texas and Utah, designed to help improve traffic safety for all road users (https://ibn.fm/8u7Hf). The deployment of lidar technology in Arlington and Irving, Texas as well as in Salt Lake City, Utah has been designed to enable operators to monitor pedestrians’ walking speeds, examine pedestrian and driver adherence to road safety regulations, as well as track ‘near misses’ for pedestrians and vehicles. Going forward, lidar could help city authorities tailor traffic signals to travelers’ needs, potentially allowing for the adjustment of signal timing in real time as well as potentially warning vehicles of potential unseen hazards ahead.

Dr. Jun Pei, CEO of Cepton commented on the deployment of Cepton’s Lidar solutions within the United States’ traffic infrastructure, “Pedestrian safety is essential to people-oriented transportation. We are thrilled that Cepton’s technology has been utilized in such ground-breaking studies and deployments that could revolutionize the way intersections are designed and operated. Our advanced lidar perception solution is designed to provide accurate, real-time 3D analytics that ultimately helps improve the walkability of streets. I am excited to see Helius deployed in more U.S. cities to help transform America’s traffic infrastructure, making safe, smart mobility accessible to everyone.”

Although the use of lidar within road safety infrastructure within the U.S. remains at a relatively nascent stage, the technology has rapidly obtained its acceptance. In early 2022, Cepton announced that its technology was being used to facilitate lidar-based vehicle detection in Cape Town, South Africa. City authorities used Cepton’s lidars to enable pedestrian and vehicle classification. Enabled by lidar, and with an AI platform to understand how both interact with the city environment, allowed for the collection of critical information needed to facilitate both traffic management and urban planning (https://ibn.fm/7IM9W).

In February 2022, Cepton announced a multi-million contract with a leading U.S. tolling system operator, where Cepton lidars will be deployed nationwide to enable accurate and intelligent tolling applications. Cepton has been shipping products to the customer to enable free-flow e-tolling systems on several major tollways located in the Tri-State area and Northern California.

Since its inception in 2016, Cepton has witnessed its innovative lidar based solutions rapidly superseding their original stated goal of facilitating advanced driver assistance systems (“ADAS”) and autonomous vehicle development, with the company’s Helius(TM) Smart Lidar System now also being used to support smart city infrastructure and traffic management systems the world over.

With the company seeking to build upon their recent success, Cepton have just announced the addition of Luis Gonçalves to their Detroit team as the company’s Director of Customer Programs (https://ibn.fm/vjGwD). Boasting extensive experience, having worked at both General Motors and Honda in the past, the industry veteran will be charged with supporting the company’s volume production ramp in support of its lead OEM customers as well as to garner future production awards from other automotive customers.

“Cepton is pioneering the mass-market commercialization of lidar, and I am excited to become part of its vision of enabling safe and autonomous transportation for everyone,” said Gonçalves. “In my previous role at GM, I became very familiar with Cepton lidars through extensive benchmarking and testing efforts on real vehicles, in real-world scenarios. I hope to contribute to Cepton’s successful execution of its flagship lidar program through the production validation and volume production ramp phases this year. I also look forward to applying my learnings from the automotive industry to help solidify Cepton’s next series production award.”

‍For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

GolfLync just received over 200 5-star reviews on the Apple App Store, performing exceptionally well in a space where sports apps averaged 3.97 and social networking apps posted a mere 3.73 in Q2 2022

• The platform matches golfers of all skill levels looking for a game through its smartphone app, becoming the go-to social network for golfers
• The app’s warm reception is seen as a reflection of its exceptional user experience, made possible by the built-in logic that allows users to get the perfect match with whomever they share similar interests and on-course preferences

GolfLync, offering a platform through its smartphone app that matches golfers of all skill levels looking for a game, just affirmed its status as the go-to “social network for golfers” with over 200 5-star ratings on the Apple App Store. The ratings reflect the warm reception the app has received thus far, the level of thoughtfulness and detail that went into its development, and the real user value that GolfLync delivers to the growing community of golf enthusiasts around the country.

Ratings are the way users find the top APPs in a category and GolfLync is significantly higher than the industry average, with sports apps averaging 3.97 and social networking apps posting a mere 3.73 (https://ibn.fm/s38A2). GolfLync delivers an exceptional, tailored experience to golfers which has been instrumental in amassing over 200 5-star reviews on the App Store.

It’s all made possible by the app’s matching logic that connects players that share similar interests with on-course preferences. “[GolfLync] Basically operates like Tinder for golfers,” noted Noah DiPasquale, the Co-Founder, and CEO of GolfLync Inc. “The reason I say the Tinder component is because there is some logic built into it. So if you like to drink on the course, or smoke, or play music, or gamble, you’ll have the opportunity to meet everybody in your area that has similar preferences,” he added (https://ibn.fm/0vitU).

The app is built to help golfers looking to grow their golf network and find other players with similar interests, and setup local groups and events, thus also growing the app’s community. With the popularity of golf having posted a steady rise in recent years, there is a growing demand for a platform that offers such features. GolfLync understands the demand, providing an app that meets users’ personal requirements, and thus driving a positive user experience. The 5-star rating on the App Store reflects an unmatched understanding of the sport while highlighting the company’s commitment to growing the golf community, and the game.

You can download the GolfLync app using the following links:
Android: https://ibn.fm/JjKJQ
iPhone: https://ibn.fm/bGEs7

For more information, visit the company’s website at www.GolfLync.com.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF